Medical disclaimer: This article is for general informational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription-only medications in Australia. Consult your GP or a specialist before starting, stopping, or changing any weight management treatment.
Saxenda (liraglutide 3 mg) and Wegovy (semaglutide 2.4 mg) are both GLP-1 receptor agonists approved by the Therapeutic Goods Administration (TGA) for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity. Despite sharing the same receptor target, they differ substantially in pharmacokinetics, clinical efficacy, dosing schedules, and their current role in Australian clinical practice.
Understanding those differences matters. For patients and clinicians weighing up options, the choice between a daily injection with a well-established long-term safety record and a weekly injection with markedly superior weight loss outcomes is rarely straightforward.
GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by L-cells in the small intestine in response to food. Its natural half-life is less than two minutes because the enzyme dipeptidyl peptidase-4 (DPP-4) rapidly degrades it. Both liraglutide and semaglutide are engineered analogues that resist DPP-4 degradation, allowing sustained receptor activation.
At physiological and pharmacological doses, GLP-1 receptor agonists produce several overlapping effects:
Where liraglutide and semaglutide diverge pharmacokinetically is primarily half-life. Liraglutide has a plasma half-life of approximately 13 hours, which is why daily injection is required to maintain therapeutic exposure. Semaglutide has a half-life of roughly 165–184 hours (about one week), achieved through a structural modification that enhances albumin binding and reduces renal clearance. This prolonged half-life enables once-weekly dosing and allows plasma concentrations to accumulate to a higher steady-state level — a key driver of its substantially greater weight loss efficacy.
Ongoing GLP-1 peptide analogue research continues to explore structural modifications that may push half-lives even further and improve receptor selectivity, including dual and triple agonists targeting GIP and glucagon receptors alongside GLP-1.
The weight loss outcomes between these two medications are not comparable. Head-to-head trial data, and the broader body of evidence, consistently place semaglutide 2.4 mg significantly ahead.
| Parameter | Saxenda (liraglutide 3 mg) | Wegovy (semaglutide 2.4 mg) |
|---|---|---|
| Key trial | SCALE Obesity and Prediabetes | STEP-1 |
| Trial duration | 56 weeks | 68 weeks |
| Mean body weight reduction | ~5–8% from baseline | ~15–17% from baseline |
| Participants achieving ≥5% weight loss | ~62% | ~86% |
| Participants achieving ≥10% weight loss | ~33% | ~69% |
| Participants achieving ≥15% weight loss | ~16% | ~50% |
| Injection frequency | Daily | Weekly |
SCALE trial (liraglutide): In the pivotal SCALE Obesity and Prediabetes trial, 3731 adults without diabetes received liraglutide 3 mg or placebo for 56 weeks alongside lifestyle counselling. Mean weight loss in the liraglutide group was 8.4 kg (approximately 8% of body weight) versus 2.8 kg in the placebo group.
STEP-1 trial (semaglutide): The STEP-1 trial enrolled 1961 adults without diabetes over 68 weeks. Participants receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight — more than double the proportional loss seen with liraglutide — compared with 2.4% in the placebo group.
STEP-8 head-to-head trial: The most clinically definitive comparison came from STEP-8, a 68-week randomised controlled trial that directly compared semaglutide 2.4 mg weekly against liraglutide 3 mg daily in adults with overweight or obesity without diabetes. Semaglutide produced a mean weight reduction of 15.8% versus 6.4% for liraglutide — a difference of 9.4 percentage points that was statistically and clinically significant. Semaglutide also outperformed on every secondary endpoint including waist circumference reduction and proportion achieving ≥10% and ≥15% weight loss thresholds.
Both medications share a GLP-1-driven side effect profile, dominated by gastrointestinal symptoms that are typically dose-dependent and most intense during dose escalation.
Because semaglutide achieves greater receptor activation at steady state, gastrointestinal side effects are generally more pronounced during titration compared to liraglutide, though both are manageable with a slow titration protocol and dietary adjustments such as smaller meals and avoiding high-fat foods.
Thyroid C-cell tumours: Rodent studies showed a dose-dependent increase in thyroid C-cell adenomas and carcinomas with both liraglutide and semaglutide. The relevance of these findings to humans is uncertain, but both medications carry a black-box warning. Both agents are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).
Pancreatitis: An increased risk of acute pancreatitis has been observed with GLP-1 receptor agonists as a class. Both liraglutide and semaglutide should be used with caution in patients with a history of pancreatitis, and discontinued if acute pancreatitis is suspected.
Gallbladder disease: Both agents are associated with an increased incidence of cholelithiasis (gallstones) and cholecystitis, likely related to reduced gallbladder motility.
Injection site reactions: Mild local reactions are possible but less common than with insulin.
Cardiovascular effects: The LEADER trial demonstrated a cardiovascular benefit for liraglutide in high-risk patients with type 2 diabetes. The SELECT trial confirmed a cardiovascular mortality and morbidity benefit for semaglutide 2.4 mg in adults with overweight/obesity and established cardiovascular disease but without diabetes — a finding that influenced its expanded clinical use.
Slow titration is essential for both medications to minimise gastrointestinal side effects and improve tolerability.
Liraglutide is titrated over approximately five weeks:
If the patient cannot tolerate a dose increase, the current dose can be maintained for an additional week before escalating. Treatment should be discontinued if the patient has not lost at least 5% of initial body weight after 12 weeks on the 3.0 mg dose.
Semaglutide's titration is slower and longer, reflecting the higher target dose and longer half-life:
This 16-week titration is considerably longer than liraglutide's five-week schedule. Patients and clinicians should set realistic expectations — meaningful weight loss typically becomes apparent only at or near the maintenance dose.
Australia's Pharmaceutical Benefits Scheme (PBS) coverage significantly affects accessibility and out-of-pocket cost for both medications.
Saxenda (liraglutide 3 mg): Was listed on the PBS for chronic weight management in eligible patients. PBS eligibility broadly required a BMI of 30 kg/m² or above, or 27 kg/m² with a weight-related comorbidity, alongside failure of lifestyle interventions.
Wegovy (semaglutide 2.4 mg): Listed on the PBS from 2024, with similar eligibility criteria — BMI of 30 kg/m² or above, or at least 27 kg/m² with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease). Given its substantially superior efficacy demonstrated in the STEP trials and the head-to-head STEP-8 data, Wegovy has largely superseded Saxenda as the preferred GLP-1 agent for weight management in Australian clinical practice.
| Scenario | Approximate Monthly Cost |
|---|---|
| PBS concessional (Wegovy) | ~$31 AUD |
| PBS general patient (Wegovy) | ~$45 AUD |
| Private (no PBS, Wegovy) | $200–$350 AUD |
| Private (no PBS, Saxenda) | $150–$260 AUD |
PBS costs are subject to change. Patients who do not meet PBS criteria, or who access these medications through private prescriptions or compounding pharmacies, face substantially higher costs. Note that compounded semaglutide or liraglutide products are not TGA-approved and their safety and efficacy are not guaranteed.
Despite semaglutide's superior efficacy, there are clinical scenarios where liraglutide remains a reasonable choice.
For patients requiring even greater weight loss than Wegovy delivers, see our guide to tirzepatide (Mounjaro) as the next step, a dual GIP/GLP-1 agonist that has demonstrated mean weight loss exceeding 20% in the SURMOUNT trials.
One of the most consistent findings across GLP-1 agonist trials is that weight loss is not sustained after discontinuation. The STEP-4 extension study found that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. Similar patterns are observed with liraglutide.
This reflects the underlying biology: GLP-1 receptor agonists suppress appetite pharmacologically, and the physiological drivers of weight regain — including adaptive reductions in resting metabolic rate and persistent hormonal changes that increase hunger — reassert themselves after the drug is withdrawn.
Strategies to minimise regain include:
Saxenda and Wegovy share a mechanism of action but differ substantially in pharmacokinetic profile, dosing schedule, clinical efficacy, and their current position in Australian treatment algorithms.
The evidence from STEP-8 is unambiguous: semaglutide 2.4 mg weekly produces roughly 2.5 times the proportional weight loss of liraglutide 3 mg daily, with semaglutide outperforming on every measured endpoint. For most patients seeking pharmacological weight management in Australia in 2026, Wegovy will be the preferred first-line GLP-1 option — particularly given comparable PBS pricing.
Saxenda retains a role for patients with specific clinical needs, contraindications to semaglutide, or established tolerability profiles that support its continued use. As with all prescription treatments for obesity, the medication is most effective when integrated into a comprehensive program that includes dietary modification, physical activity, and behavioural support.
All medication information is based on TGA-approved product information and published clinical trial data current as of May 2026. PBS listing criteria and pricing are subject to change — verify current eligibility and costs with your prescribing clinician or the PBS website.
A research-backed explainer on orforglipron (Foundayo) — the first oral small-molecule GLP-1 receptor agonist approved for weight loss, why no-restriction dosing matters, what the ATTAIN trials showed, and how it compares to injectables and oral semaglutide.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.
Cagrilintide is a once-weekly long-acting amylin analog, and Cagrisema combines it with semaglutide. This guide covers the REDEFINE Phase 3 trial results, how amylin co-agonism works, why the headline weight loss disappointed market expectations despite being clinically significant, and what the Australian regulatory path looks like.